NATIONAL, DECEMBER 6th, 2024 (TGN): Private equity major TPG Capital backed Sai Life Sciences Limited announced today on Friday that it has fixed a price band of Rs 522-549 per equity share for its Rs 3,043 crore Initial Public Offer (IPO) that opens for public subscription on December 11.
The intial share sale will conclude on December 13, and the bidding for the anchor portion will open for a day on December 10, the company announced.
The IPO is a combination of a fresh issue of equity shares worth up to Rs 950 crore and an Offer For Sale (OFS) of up to 3.81 crore equity shares by a promoter, investor shareholders and other shareholders, according to the Red Herring Prospectus (RHP).
Under the OFS, one of the promoter entities — Sai Quest Syn Pvt Ltd — and investor shareholders — TPG Asia VII SF Pte Ltd, HBM Private Equity India — will offload their respective stakes.
Bharathi Srivari, Anita Rudraraju Nandyala, Raju Penmasta, Dirk Walter Sartor, Jagdish Viswanath Dore, Rajagopal Srirama Tatta and K Pandu Ranga Raju were the other selling shareholders who will also divest their stakes in the company.
The Hyderabad based Sai Life Sciences had filed its IPO papers with the Securities and Exchange Board of India (SEBI) in July 2024 and obtained the markets regulator’s approval in November, to float the IPO.At the upper end of the price band, the company is going to fetch around Rs 3,042.62 crore from the IPO.
Of the IPO proceeds, funds limiting to Rs 720 crore will be used for debt payment and a portion will be used for corporate general purposes.
Investors can bid for a minimum of 27 equity shares and in multiples thereafter. Sai Life Sciences provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule New Chemical Entities (NCE), to global pharmaceutical innovator companies and biotechnology firms.
During the six-month ended September 2024, Sai Life Sciences reported a total income of Rs 693.35 crore against Rs 656.8 crore a year ago. It posted a net profit for the six months at Rs 28.01 crore as compared to a loss of Rs 12.92 crore last year.
Kotak Mahindra Capital Company Ltd, IIFL Capital Services Ltd (formerly IIFL Securities Ltd), Jefferies India and Morgan Stanley India Company are the book running lead managers, while KFin Technologies is the registrar for the IPO.
The company’s shares are proposed to be listed on the BSE and National Stock Exchange (NSE).
Sai Life Sciences is the fastest-growing contract research, development, and manufacturing organization (CRDMO). It is also one of the few CRDMOs to have research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), United States (US), and Manchester, United Kingdom (UK), complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India.
The company has served more than 280 innovator pharmaceutical companies, including 18 of the top 25 pharmaceutical companies, across regulated markets, including the US, the UK, Europe, and Japan. It also provides CRO services to more than 60 customers on an ongoing basis, for their integrated drug discovery programs. As of 31 March 2024, its CDMO product portfolio included more than 150 innovative pharmaceutical products, including 38 products that were supplied for the manufacturing of 28 commercial drugs.
As of 31 March 2024, the company has 2,845 employees globally, including 2,125 scientific staff, with the majority of the scientific team holding advanced degrees, including 276 PhDs and 1,343 master’s degrees.
